Cargando…
Radiotherapeutic treatment options for oligotopic malignant liver lesions
BACKGROUND: Several radiotherapeutic approaches for patients with oligotopic malignant liver lesions unfit for surgical resection exist. The most advanced competitive techniques are high-dose-rate (HDR) brachytherapy, Cyberknife, volume-modulated-arc therapy (VMAT) and Tomotherapy. We evaluated the...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970808/ https://www.ncbi.nlm.nih.gov/pubmed/33726751 http://dx.doi.org/10.1186/s13014-021-01779-5 |
_version_ | 1783666485771632640 |
---|---|
author | Wust, Peter Beck, Marcus Dabrowski, Robert Neumann, Oliver Zschaeck, Sebastian Kaul, David Modest, Dominik P. Stromberger, Carmen Gebauer, Bernhard Ghadjar, Pirus |
author_facet | Wust, Peter Beck, Marcus Dabrowski, Robert Neumann, Oliver Zschaeck, Sebastian Kaul, David Modest, Dominik P. Stromberger, Carmen Gebauer, Bernhard Ghadjar, Pirus |
author_sort | Wust, Peter |
collection | PubMed |
description | BACKGROUND: Several radiotherapeutic approaches for patients with oligotopic malignant liver lesions unfit for surgical resection exist. The most advanced competitive techniques are high-dose-rate (HDR) brachytherapy, Cyberknife, volume-modulated-arc therapy (VMAT) and Tomotherapy. We evaluated the optimal technique by a planning study for a single ablative dose with different lesion sizes. METHODS: We compared dose distributions of HDR-brachytherapy with stereotactic ablative radiotherapy using the Cyberknife, VMAT or Tomotherapy. Tumor-control-probabilities (TCP), normal-tissue-complication-probabilities (NTCP) were determined in a theoretical framework applying a single dose of 20 Gy (demanding 95% coverage) for intrahepatic lesions of 1–5 cm in size. We evaluated therapeutic ratios by TCP (mean dose in the lesion) relative to high-dose (conformality) or low-dose liver exposition in dependency on the lesion size for each technique. In addition, we considered treatment times and accuracy (clinical target volume vs planning target volume). RESULTS: HDR-brachtherapy has the highest therapeutic ratios with respect to high-dose as well as low-dose liver exposition even for extended lesions, and the Cyberknife being suited second best. However, for lesions ≥ 3 cm diameter the therapeutic ratios of all ablative techniques are increasingly converging, and better tolerance and shorter treatment times of noninvasive external techniques become more important. On the other hand, mean tumor doses of HDR-brachytherapy of near 60 Gy are unattainable by the other techniques gaining only 22–34 Gy, and the conformality of HDR-brachytherapy is still rather good for lesions ≥ 3 cm diameter. CONCLUSIONS: HDR-brachytherapy is by far the most effective technique to treat intrahepatic lesions by a single fraction, but sparing of the surroundings declines with increasing lesion size and approaches the benchmarks of external beam radiosurgery techniques. External beam radiotherapy has the advantage to use suitable fractionation schedules. |
format | Online Article Text |
id | pubmed-7970808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79708082021-03-19 Radiotherapeutic treatment options for oligotopic malignant liver lesions Wust, Peter Beck, Marcus Dabrowski, Robert Neumann, Oliver Zschaeck, Sebastian Kaul, David Modest, Dominik P. Stromberger, Carmen Gebauer, Bernhard Ghadjar, Pirus Radiat Oncol Research BACKGROUND: Several radiotherapeutic approaches for patients with oligotopic malignant liver lesions unfit for surgical resection exist. The most advanced competitive techniques are high-dose-rate (HDR) brachytherapy, Cyberknife, volume-modulated-arc therapy (VMAT) and Tomotherapy. We evaluated the optimal technique by a planning study for a single ablative dose with different lesion sizes. METHODS: We compared dose distributions of HDR-brachytherapy with stereotactic ablative radiotherapy using the Cyberknife, VMAT or Tomotherapy. Tumor-control-probabilities (TCP), normal-tissue-complication-probabilities (NTCP) were determined in a theoretical framework applying a single dose of 20 Gy (demanding 95% coverage) for intrahepatic lesions of 1–5 cm in size. We evaluated therapeutic ratios by TCP (mean dose in the lesion) relative to high-dose (conformality) or low-dose liver exposition in dependency on the lesion size for each technique. In addition, we considered treatment times and accuracy (clinical target volume vs planning target volume). RESULTS: HDR-brachtherapy has the highest therapeutic ratios with respect to high-dose as well as low-dose liver exposition even for extended lesions, and the Cyberknife being suited second best. However, for lesions ≥ 3 cm diameter the therapeutic ratios of all ablative techniques are increasingly converging, and better tolerance and shorter treatment times of noninvasive external techniques become more important. On the other hand, mean tumor doses of HDR-brachytherapy of near 60 Gy are unattainable by the other techniques gaining only 22–34 Gy, and the conformality of HDR-brachytherapy is still rather good for lesions ≥ 3 cm diameter. CONCLUSIONS: HDR-brachytherapy is by far the most effective technique to treat intrahepatic lesions by a single fraction, but sparing of the surroundings declines with increasing lesion size and approaches the benchmarks of external beam radiosurgery techniques. External beam radiotherapy has the advantage to use suitable fractionation schedules. BioMed Central 2021-03-16 /pmc/articles/PMC7970808/ /pubmed/33726751 http://dx.doi.org/10.1186/s13014-021-01779-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Wust, Peter Beck, Marcus Dabrowski, Robert Neumann, Oliver Zschaeck, Sebastian Kaul, David Modest, Dominik P. Stromberger, Carmen Gebauer, Bernhard Ghadjar, Pirus Radiotherapeutic treatment options for oligotopic malignant liver lesions |
title | Radiotherapeutic treatment options for oligotopic malignant liver lesions |
title_full | Radiotherapeutic treatment options for oligotopic malignant liver lesions |
title_fullStr | Radiotherapeutic treatment options for oligotopic malignant liver lesions |
title_full_unstemmed | Radiotherapeutic treatment options for oligotopic malignant liver lesions |
title_short | Radiotherapeutic treatment options for oligotopic malignant liver lesions |
title_sort | radiotherapeutic treatment options for oligotopic malignant liver lesions |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970808/ https://www.ncbi.nlm.nih.gov/pubmed/33726751 http://dx.doi.org/10.1186/s13014-021-01779-5 |
work_keys_str_mv | AT wustpeter radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions AT beckmarcus radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions AT dabrowskirobert radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions AT neumannoliver radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions AT zschaecksebastian radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions AT kauldavid radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions AT modestdominikp radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions AT strombergercarmen radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions AT gebauerbernhard radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions AT ghadjarpirus radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions |